114 related articles for article (PubMed ID: 2979265)
61. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.
Abelö A; Eriksson UG; Karlsson MO; Larsson H; Gabrielsson J
J Pharmacol Exp Ther; 2000 Nov; 295(2):662-9. PubMed ID: 11046103
[TBL] [Abstract][Full Text] [Related]
62. The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection.
Bercík P; Verdú EF; Armstrong D; Idström JP; Cederberg C; Markert M; Crabtree JE; Stolte M; Blum AL
Am J Gastroenterol; 2000 Apr; 95(4):947-55. PubMed ID: 10763943
[TBL] [Abstract][Full Text] [Related]
63. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
[TBL] [Abstract][Full Text] [Related]
64. Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity.
Kato S; Ebina K; Fujii K; Chiba H; Nakagawa H
J Pediatr; 1996 Mar; 128(3):415-21. PubMed ID: 8774516
[TBL] [Abstract][Full Text] [Related]
65. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
Maton PN
Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
[TBL] [Abstract][Full Text] [Related]
66. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
[TBL] [Abstract][Full Text] [Related]
67. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734
[TBL] [Abstract][Full Text] [Related]
68. The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole.
Zimmermann T; Yeates RA; Riedel KD; Lach P; Laufen H
Int J Clin Pharmacol Ther; 1994 Sep; 32(9):491-6. PubMed ID: 7820333
[TBL] [Abstract][Full Text] [Related]
69. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.
Larson C; Cavuto NJ; Flockhart DA; Weinberg RB
Dig Dis Sci; 1996 Mar; 41(3):475-9. PubMed ID: 8617118
[TBL] [Abstract][Full Text] [Related]
70. Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients.
Hewson EG; Yeomans ND; Angus PW; Shulkes A; Brook CW; Sewell RB; Smallwood RA
Gut; 1988 Dec; 29(12):1715-20. PubMed ID: 3220312
[TBL] [Abstract][Full Text] [Related]
71. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
Andersson T; Hassall E; Lundborg P; Shepherd R; Radke M; Marcon M; Dalväg A; Martin S; Behrens R; Koletzko S; Becker M; Drouin E; Göthberg G
Am J Gastroenterol; 2000 Nov; 95(11):3101-6. PubMed ID: 11095324
[TBL] [Abstract][Full Text] [Related]
72. Effect of repeated oral administration of BY 1023/SK&F 96022--a new substituted benzimidazole derivative--on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.
Simon B; Müller P; Marinis E; Lühmann R; Huber R; Hartmann R; Wurst W
Aliment Pharmacol Ther; 1990 Aug; 4(4):373-9. PubMed ID: 2151747
[TBL] [Abstract][Full Text] [Related]
73. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
[TBL] [Abstract][Full Text] [Related]
74. Omeprazole: pharmacology, pharmacokinetics and interactions.
Oosterhuis B; Jonkman JH
Digestion; 1989; 44 Suppl 1():9-17. PubMed ID: 2691315
[TBL] [Abstract][Full Text] [Related]
75. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.
Maton PN; Vinayek R; Frucht H; McArthur KA; Miller LS; Saeed ZA; Gardner JD; Jensen RT
Gastroenterology; 1989 Oct; 97(4):827-36. PubMed ID: 2777040
[TBL] [Abstract][Full Text] [Related]
76. Intravenous omeprazole: effect of a loading dose on 24-h intragastric pH.
Andersen J; Ström M; Naesdal J; Leire K; Walan A
Aliment Pharmacol Ther; 1990 Feb; 4(1):65-72. PubMed ID: 2104075
[TBL] [Abstract][Full Text] [Related]
77. Intravenous omeprazole rapidly raises intragastric pH.
Walt RP; Reynolds JR; Langman MJ; Smart HL; Kitchingman G; Somerville KW; Hawkey CJ
Gut; 1985 Sep; 26(9):902-6. PubMed ID: 4029717
[TBL] [Abstract][Full Text] [Related]
78. Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole.
Robinson M; Rodriguez-Stanley S; Ciociola AA; Filinto J; Zubaidi S; Miner PB; Gardner JD
Dig Dis Sci; 2002 Feb; 47(2):265-73. PubMed ID: 11855540
[TBL] [Abstract][Full Text] [Related]
79. Oral phenytoin pharmacokinetics during omeprazole therapy.
Prichard PJ; Walt RP; Kitchingman GK; Somerville KW; Langman MJ; Williams J; Richens A
Br J Clin Pharmacol; 1987 Oct; 24(4):543-5. PubMed ID: 3689634
[TBL] [Abstract][Full Text] [Related]
80. Gastric pH, sevelamer hydrochloride and omeprazole.
Capitanini A; Lupi A; Osteri F; Petrone I; Del Corso C; Straniti M; Gallieni M; Rossi A
Clin Nephrol; 2005 Oct; 64(4):320-2. PubMed ID: 16240906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
